Baxter International
Q1 FY26 Mar 31, 2026
Revenue$2.7B
+3% year over year
Gross profit$0.9B
Operating profit$0.1B
Net profit$0B
-1% margin
Numbers and detail
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 2.7 | 100% | +3% |
| Medical Products & Therapies | 1.3 | 48% | |
| Healthcare Systems & Technologies | 0.7 | 26% | |
| Pharmaceuticals | 0.6 | 22% | +7% |
| Other | 0.1 | 4% | +15% |
| Cost of revenue | −1.8 | 67% | |
| Gross profit | 0.9 | 33% margin | +0pp |
| Research & development | −0.1 | 5% | +0pp |
| SG&A | −0.7 | 27% | +0pp |
| Operating profit | 0.1 | 2% margin | +0pp |
| Interest & other costs | −0.1 | ||
| Net profit | 0 | -1% | −5pp |
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 3 | 100% | +8% |
| US | 1.6 | 53% | +3% |
| Western Europe Canada Japan… | 1 | 33% | +15% |
| Eastern Europe Middle East Africa… | 0.4 | 13% | +14% |
| Cost of revenue | −2.4 | 80% | |
| Gross profit | 0.6 | 19% margin | −15pp |
| Research & development | −0.1 | 4% | +0pp |
| SG&A | −0.8 | 26% | +0pp |
| Other | −0.4 | 14% | +0pp |
| Operating profit | -0.7 | -25% margin | +0pp |
| Tax | −0.3 | ||
| Interest & other costs | −0.1 | ||
| Net profit | -1.1 | -38% | −19pp |
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 2.8 | 100% | +5% |
| US | 1.5 | 54% | +3% |
| Western Europe Canada Japan… | 0.9 | 32% | +10% |
| Eastern Europe Middle East Africa… | 0.4 | 14% | +2% |
| Cost of revenue | −1.9 | 68% | |
| Gross profit | 1 | 34% margin | −5pp |
| Research & development | −0.1 | 4% | −1pp |
| SG&A | −0.7 | 25% | −3pp |
| Operating profit | 0.2 | 6% margin | +0pp |
| Tax | −0.2 | ||
| Net profit | 0 | -2% | −7pp |
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 2.8 | 100% | +4% |
| US | 1.5 | 54% | +3% |
| Western Europe Canada Japan… | 0.9 | 32% | +9% |
| Eastern Europe Middle East Africa… | 0.3 | 11% | −1% |
| Cost of revenue | −1.8 | 64% | |
| Gross profit | 1 | 35% margin | −3pp |
| Research & development | −0.1 | 5% | +0pp |
| SG&A | −0.7 | 26% | −1pp |
| Operating profit | 0.2 | 7% margin | +0pp |
| Interest & other costs | −0.1 | ||
| Net profit | 0.1 | 3% | +15pp |
Quarter by quarter
Pick a quarter and the diagram above changes. Bars compare revenue across the quarters we hold.
| Quarter | Period | Reported | Revenue | Year over year | Operating margin | Net profit | Net margin |
|---|---|---|---|---|---|---|---|
| Q1 FY26 | Mar 31, 2026 | Apr 30, 2026 | $2.7B | +3% | 4% | $0B | -1% |
| Q4 FY25 | Oct 1 – Dec 31, 2025 | Feb 12, 2026 | $3B | +8% | -23% | $-1.1B | -38% |
| Q3 FY25 | Jul 1 – Sep 30, 2025 | Nov 4, 2025 | $2.8B | +5% | 7% | $0B | -2% |
| Q2 FY25 | Apr 1 – Jun 30, 2025 | Aug 5, 2025 | $2.8B | +4% | 7% | $0.1B | 3% |
New results in your inbox
When a big company reports, you get the diagram before anyone has time to comment on it. No spam, one-click unsubscribe.